SCHEMBL503304

SCHEMBL503304

O=C(O)CCCC(=O)c1ccccc1

nearest known ligand 0.88

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 6/20 0.88
HDAC8 Q9BY41 6/20 0.88
HDAC3 O15379 2/20 0.88
HDAC4 P56524 2/20 0.88
HDAC7 Q8WUI4 2/20 0.88
HDAC2 Q92769 2/20 0.88
HDAC10 Q969S8 2/20 0.88
HDAC11 Q96DB2 2/20 0.88
HDAC6 Q9UBN7 2/20 0.88
HDAC9 Q9UKV0 2/20 0.88
HDAC5 Q9UQL6 2/20 0.88
TDP1 Q9NUW8 3/20 0.75
L3MBTL1 Q9Y468 2/20 0.75
LMNA P02545 2/20 0.75
MAPT P10636 2/20 0.75
NR4A2 P43354 1/20 0.75
GAA P10253 2/20 0.67
CYP2C19 P33261 2/20 0.67
ALDH1A1 P00352 1/20 0.67
RAB9A P51151 4/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6608564 0.98 HDAC1 (0.84) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL517169 0.95 HDAC1 (0.96) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL9356269 0.93 HDAC1 (1.00) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL3378075 0.93 HDAC1 (1.00) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL3383102 0.93 HDAC1 (1.00) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL6604478 0.93 HDAC1 (0.92) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL7824358 0.93 HDAC1 (1.00) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL9352420 0.93 HDAC1 (1.00) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL9663087 0.93 HDAC1 (1.00) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL3381106 0.93 HDAC1 (1.00) HDAC1HDAC8HDAC3HDAC4HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 471 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025151884-A1 USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE PARSONS C LOWELL (US) 2025-07-17 WO claimed
US-11884628-B2 Method for synthesizing lactam derivatives without use of catalyst GUIZHOU UNIVERSITY (CN) 2024-01-30 US claimed
US-20220177429-A1 METHOD FOR SYNTHESIZING LACTAM DERIVATIVES WITHOUT USE OF CATALYST GUIZHOU UNIVERSITY (CN) 2022-06-09 US claimed
CN-112824392-A Quinoline derivative and preparation method and application thereof 中国农业大学 2021-05-21 CN claimed
WO-2020228170-A1 CATALYST-FREE SYNTHESIS METHOD FOR LACTAM DERIVATIVE 贵州大学 2020-11-19 WO claimed
CN-109942473-B Method for synthesizing lactam derivative without catalyst 贵州大学 2020-09-15 CN claimed
CN-107298640-B Preparation method and application of methylene ketone compound 曲阜师范大学 2020-08-04 CN claimed
CN-111004291-A Etimicin derivative and synthetic method thereof 卓和药业集团有限公司 2020-04-14 CN claimed
CN-111004292-A Gentamicin derivative and preparation method thereof 卓和药业集团有限公司 2020-04-14 CN claimed
CN-110845554-A Synthesis method of etimicin sulfate 卓和药业集团有限公司 2020-02-28 CN claimed
WO-2005113495-A1 METHOD FOR PRODUCING DIPHENYL AZETIDINONE DERIVATIVES SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2005-12-01 WO claimed
WO-2005110970-A1 OXO-SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2005-11-24 WO claimed
US-6946025-B2 Process for preparing tetra-amide compounds XEROX CORPORATION (US) 2005-09-20 US claimed
US-20050090690-A1 Process for preparing tetra-amide compounds XEROX CORPORATION 2005-04-28 US claimed
US-6861550-B2 Polyhydroxyalkanoate containing 3-hydroxybenzoylalkanoic acid as monomer unit, and method for producing the same CANON KABUSHIKI KAISHA (JP) 2005-03-01 US claimed
US-20030100084-A1 Polyhydroxyalkanoate containing 3-hydroxybenzoylalkanoic acid as monomer unit, and method for producing the same CANON KABUSHIKI KAISHA (JP) 2003-05-29 US claimed
US-6398857-B1 ACCUSTIC PIEZOELECTRIC; HOT MELT INK JET PRINTING; BENZOIC ACID VEHICLE; ALKYL OR PHENYL CARBOXYLIC ACID VISCOSITY MODIFIER; RETAINS DESIRED HARDNESS XEROX CORPORATION 2002-06-04 US claimed
EP-1130042-A2 Polyhydroxyalkanoate containing 3-hydroxybenzoylalkanoic acid as monomer unit, and method for producing the same CANON KABUSHIKI KAISHA (JP) 2001-09-05 EP claimed
EP-0619290-B1 Salts of alkaline earth metals and transition metals as well as complexes of transition metals of ketocarboxylic acids and their use as corrosion inhibitors CIBA GEIGY AG (CH) 1996-10-09 EP claimed
EP-0164101-B1 BENZOYLPROPIONIC ACID DERIVATIVES, THEIR USE AND PHARMACEUTICAL COMPOSITIONS TAISHO PHARMACEUTICAL CO. LTD (JP) 1988-09-07 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11884628-B2 Method for synthesizing lactam derivatives without use of catalyst COASY, SI, NAAA HDAC1 1075/4885HDAC8 665/4885HDAC3 2248/4885
US-20050090690-A1 Process for preparing tetra-amide compounds TAF9, TAF5, TAF1 HDAC1 553/4885HDAC8 623/4885HDAC3 849/4885
US-20220177429-A1 METHOD FOR SYNTHESIZING LACTAM DERIVATIVES WITHOUT USE OF CATALYST COASY, SI, NAAA HDAC1 1075/4885HDAC8 665/4885HDAC3 2248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.